Growth Strategy
Global Expansion Vision
Once proven in Tulum, our model can be replicated across multiple jurisdictions, creating a global network of transformation centers.
The Platform Opportunity
Transformational Epicenter is designed from day one as a replicable platform. Standardized protocols, training programs, and technology enable efficient multi-location expansion while maintaining quality and brand consistency.
3+
Target Locations
By 2031
$50M+
Platform Revenue
At scale
10x
Exit Multiple
Platform premium
Global
Market Access
Multi-jurisdiction
Expansion Roadmap
2026-2028
Phase 1: Tulum flagship
Prove model, optimize operations, build brand
2028-2029
Phase 2: Second location
Expand to Caribbean or Central America
2029-2031
Phase 3: Platform scale
Multi-location network, potential US entry
Target Expansion Regions
Caribbean
Legal psilocybin, growing wellness tourism
Investor-friendly, citizenship by investment
Central America
Established wellness destination, ayahuasca legal
Lake Atitlan wellness hub emerging
Europe
Decriminalized, progressive drug policy
Legal psilocybin truffles, established market
Asia-Pacific
Recently approved MDMA/psilocybin prescribing
Liberalizing psychedelic policy
Location Selection Criteria
US Market Opportunity
Watching US Regulatory Progress
Position for domestic expansion
We are closely monitoring US regulatory developments. MDMA and psilocybin are on track for FDA approval, potentially enabling US-based treatment centers within our investment horizon.
Building Platform Value
Multi-location platforms command significant premiums at exit. Strategic acquirers pay 10-12x EBITDA for proven, scalable healthcare platforms—versus 6-8x for single-location operations.
Single Location
6-8x EBITDA
Operating business
Regional Platform
8-10x EBITDA
2-3 locations
Global Platform
10-12x EBITDA
4+ locations